Increased Insulin Requirement in a Patient with Type 1 Diabetes on Rifampicin

Atkin, Stephen L.; Masson, E. A.; Bodmer, Charles; Walker, Beth; White, Michael C.

doi:10.1111/j.1464-5491.1993.tb00086.x

Cited by 20 publications

(17 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5 but like isoniazid, it may increase insulin requirements. 6 Liver and nerve toxicity from anti-TB drugs may be difficult to distinguish from diabetes-associated non-alcoholic fatty liver disease and peripheral neuropathy respectively and for those with co-morbid HIV infection with access to treatment, there is the added complication of antiretroviral-associated insulin resistance. 7 TB itself may precipitate hyperglycaemia by a stress hormone response and there is some evidence of glucose intolerance in TB patients reverting to normal in up to 75% of patients after three months of TB treatment.…”

Section: In Responsementioning

confidence: 99%

Including pharmacists on consultant-led ward rounds

Quantrill

Webbe

2011

Clinical Medicine

View full text Add to dashboard Cite

Section: In Responsementioning

confidence: 99%

Including pharmacists on consultant-led ward rounds

Quantrill

Webbe

2011

Clinical Medicine

View full text Add to dashboard Cite

“…As necessidades de insulina podem aumentar em indivíduos em uso de rifampicina, uma vez que em uma fase inicial do tratamento com esse fármaco pode ocorrer um estado de hiperglicemia associado à hiperinsulinemia, mesmo em indivíduos não diabéticos (52). Portanto, pacientes em uso de rifampicina devem realizar rigoroso monitoramento glicêmico para ajuste adequado dos agentes antidiabéticos (45).…”

Section: Tuberculoseunclassified

Distúrbios metabólicos em doenças infecciosas emergentes e negligenciadas

Ponte

Gurgel

Ponte

et al. 2010

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

SUMÁRIOA substituição gradual e progressiva das doenças infecciosas e parasitárias pelas doenças crônico-degenerativas como causas de morbidade e mortalidade, caracterizando o processo de transição epidemiológica, não tem sido observada em várias populações, em especial em países subdesenvolvidos ou em desenvolvimento, verificando-se, na realidade, uma sobreposição desses perfis (transição incompleta). Além do aumento da prevalência de distúrbios metabólicos, várias doenças infecciosas permanecem endêmicas em diversas regiões, como é o caso da hanseníase, da tuberculose, da leishmaniose, das hepatites virais, entre outras, assim como condições emergentes nas últimas décadas, como a infecção pelo HIV/Aids. Nesse contexto, nos últimos anos tem sido dada uma maior atenção para a ocorrência de distúrbios metabólicos, principalmente a partir da observação de elevada incidência dessas anormalidades associadas à infecção pelo HIV/Aids e à sua terapia com as drogas antirretrovirais. Nesta revisão são abordados aspectos clínico-epidemiológicos dos distúrbios metabólicos reportados em algumas enfermidades infectoparasitárias de relevância mundial e local (no Brasil), assim como possíveis mecanismos e fatores envolvidos nessas associações. Arq Bras Endocrinol Metab. 2010;54(9):785-92 Descritores Infecção; distúrbios metabólicos; diabetes melito; doença cardiovascular; tuberculose; HIV; Aids; hepatite; hanseníase; leishmaniose SUMMARYThe gradual and progressive replacement of infectious and parasitic by chronic diseases as causes of morbidity and mortality, characterizing the process of epidemiological transition hasn't been observed in various populations, especially in underdeveloped or developing countries characterizing a superposition of these profiles (incomplete transition). Besides the increased prevalence of metabolic disorders, various infectious diseases remain endemic in several regions, such as leprosy, tuberculosis, leishmaniasis, viral hepatitis, among others, as well as emerging diseases in recent decades, as HIV infection/Aids. In this context, more attention has been given to the occurrence of metabolic disturbances in the recent years, mainly from the observation of a high incidence of metabolic disorders associated with HIV infection/Aids, and its therapy with antiretroviral drugs. This review addresses clinical and epidemiological aspects of metabolic disturbances reported in some infectious and parasitic diseases with worldwide and local (Brazil) relevance, as well as possible mechanisms and factors involved in these associations. Arq Bras Endocrinol Metab. 2010;54(9):785-92

show abstract

“…Therefore it may cause hyperglycemia in diabetic patients using these drugs. In non-diabetics, it augments the intestinal absorption of glucose and may simulate the symptoms of diabetes (15). Isoniazid, in contrast to rifampicin, inhibits the metabolism of oral hypoglycaemic agents and may lead to an increase in the plasma levels of these drugs.…”

Section: Effects Of Anti Tubercular Drugs On the Glucose Metabolismmentioning

confidence: 99%

“…Therefore the dosage of insulin should be adjusted while adding and removing these drugs from the patients' prescriptions. Dipetidyl protease inhibitors (the gliptins), a comparatively newer class of hypoglycemic agents, have a theoretical possibility of reducing immunocompetence because of their mechanism of action [16,17]. This effect could possibly worsen the outcome of patients with TB.…”

Section: Effects Of Anti Tubercular Drugs On the Glucose Metabolismmentioning

confidence: 99%